Core Viewpoint - Sanara MedTech Inc. is set to report its third quarter 2025 financial results on November 12, 2025, before U.S. markets open, indicating ongoing transparency and communication with investors [1]. Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skin markets [4]. - The company markets and distributes a range of surgical, wound, and skin products primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Key products include CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and various advanced biologic products [4]. - Sanara's pipeline includes product candidates targeting opportunistic pathogens, wound healing, and necrotic tissue debridement, showcasing its commitment to innovation [4]. Upcoming Events - A conference call and webcast will be held on November 12, 2025, at 8:00 a.m. Eastern Time to discuss the financial results and engage in a Q&A session [2]. - The conference call can be accessed via a toll-free number, with a replay available until November 26, 2025 [2]. Investor Relations - Investor relations contacts are provided for further inquiries, indicating the company's openness to communication with stakeholders [7].

Core Viewpoint - Sanara MedTech Inc. has appointed Seth Yon as President and Chief Executive Officer, effective September 15, 2025, succeeding Ron Nixon, who will remain as Executive Chairman [1][2]. Leadership Transition - The Board of Directors unanimously voted to appoint Seth Yon, highlighting his strategic leadership and proven track record over the past seven years, during which Sanara achieved a compounded annual net revenue growth of 53% over the last three fiscal years [2]. - Ron Nixon emphasized that this transition is part of a long-term initiative to strengthen the senior leadership team for future success in the market [2]. Seth Yon's Background - Seth Yon joined Sanara in March 2018 and has held various senior management roles, including Director of Sales, National Sales Director, and President of Commercial, before becoming President and Chief Commercial Officer [2][3]. - His experience includes leading the development of sales processes and metrics, contributing to significant growth in the Sanara Surgical segment [2]. Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skin markets [4][5]. - The company markets a range of products, including CellerateRX Surgical Activated Collagen and various advanced biologic products, primarily in the North American advanced wound care and surgical tissue repair markets [4][5].

Core Viewpoint - Sanara MedTech Inc. is set to present at the Cantor Global Healthcare Conference, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical and wound care markets [1][2]. Company Overview - Sanara MedTech Inc. specializes in medical technology, particularly in surgical, chronic wound, and skin markets, with a commitment to enhancing clinical outcomes and minimizing healthcare expenditures [3]. - The company markets and distributes a range of products, including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [3]. - Sanara's product portfolio includes advanced biologic products such as ACTIGEN™ Verified Inductive Bone Matrix and BIASURGE Advanced Surgical Solution, along with wound care products like BIAKŌS Antimicrobial Skin and Wound Cleanser [3]. - The company is actively pursuing long-term strategic partnerships to develop products that improve patient outcomes while reducing overall costs [3]. Upcoming Events - Management will participate in a fireside chat presentation at the Cantor Global Healthcare Conference on September 3, 2025, at approximately 2:45 p.m. Eastern Time [1]. - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for replay after the conference [2].

Core Viewpoint - Sanara MedTech Inc. is set to report its second quarter 2025 financial results on August 13, 2025, focusing on transformative technologies in the medical field to enhance clinical outcomes and reduce healthcare costs [1][4]. Financial Results Announcement - The financial results for the quarter ending June 30, 2025, will be discussed in a conference call and webcast scheduled for August 13, 2025, at 8:00 a.m. Eastern Time [2]. - A toll-free number for the teleconference is provided, along with details for international callers and a replay option available until August 27, 2025 [2]. Company Overview - Sanara MedTech Inc. specializes in developing and commercializing technologies aimed at improving clinical outcomes in surgical, chronic wound, and skin markets [4]. - The company markets a range of products including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Sanara's product pipeline includes innovative candidates targeting opportunistic pathogens, wound healing, and tissue debridement, with a commitment to meeting quality and regulatory standards [4].

Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]

Core Insights - Sanara MedTech Inc. reported a 26% year-over-year increase in net revenue for Q1 2025, reaching $23.4 million compared to $18.5 million in Q1 2024 [6][10][15] - The company experienced a net loss of $3.5 million in Q1 2025, which is an increase from a net loss of $1.8 million in the same period last year [15][27] - Adjusted EBITDA improved to $0.7 million in Q1 2025, up from $0.3 million in Q1 2024, indicating better operational performance [16][32] Financial Performance - Net revenue increased by $4.9 million, driven by a $4.5 million (28%) rise in soft tissue repair products and a $0.4 million (18%) increase in bone fusion products [10][11] - Gross profit for Q1 2025 was $21.6 million, a 30% increase from $16.6 million in Q1 2024, with a gross margin of 92% compared to 90% in the previous year [11][12] - Operating expenses rose to $23.7 million, a 30% increase from $18.2 million in Q1 2024, primarily due to higher selling, general, and administrative expenses [12][13] Operational Developments - The company executed an exclusive license and distribution agreement with Biomimetic Innovations Ltd, acquiring U.S. marketing rights for a new bone void filler product [7][8] - Sanara expanded its executive leadership team with new appointments, including a new Chief Financial Officer [7][8] - The company is preparing to launch a pilot program for its Tissue Health Plus initiative in collaboration with a wound care provider group [8] Cash and Debt Position - As of March 31, 2025, Sanara had $20.7 million in cash and $42.8 million in principal debt obligations, with an additional borrowing capacity of $12.25 million [17][24] - The company borrowed $12.25 million under its term loan agreement, which may be used for acquisitions and working capital [7][17] Market Focus - Sanara MedTech is focused on developing transformative technologies in the surgical, chronic wound, and skincare markets, aiming to improve clinical outcomes and reduce healthcare costs [20][21] - The company markets a range of products in the advanced wound care and surgical tissue repair markets, with a strong emphasis on expanding its distribution network [20][21]

Core Viewpoint - Sanara MedTech Inc. is set to report its first quarter 2025 financial results on May 14, 2025, before U.S. markets open, indicating ongoing developments in its financial performance and business strategy [1]. Group 1: Financial Reporting - The company will host a conference call and webcast on May 14, 2025, at 8:00 a.m. Eastern Time to discuss the financial results for the quarter ended March 31, 2025, followed by a Q&A session [2]. - A telephonic replay of the conference call will be available until May 28, 2025, providing access to the discussion for those unable to attend live [2]. Group 2: Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [4]. - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Key products include CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and various advanced biologic products, indicating a diverse product portfolio [4]. - The company is actively seeking long-term strategic partnerships to enhance product offerings that improve outcomes at a lower overall cost [4].